Published : Jun-2020
No. of Pages : 44
1.1 List of Tables
1.2 List of Figures
2 Hodgkin Lymphoma: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Hodgkin Lymphoma (2019-2029)
3.5.1 Diagnosed Incident Cases of Hodgkin Lymphoma
3.5.2 Diagnosed Incident Cases of Classical Hodgkin Lymphoma
3.5.3 Age-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma
3.5.4 Sex-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma
3.5.5 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Stage
3.5.6 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Subtypes
3.5.7 Five-Year Diagnosed Prevalent Cases of Classical Hodgkin Lymphoma
3.5.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant Hodgkin Lymphoma
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 COVID-19 Impact
3.6.3 Limitations of Analysis
3.6.4 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: HL Cancer Stages
Table 4: Risk Factors and Comorbidities for HL
List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, 2019 and 2029
Figure 2: 8MM, Diagnosed Incidence Rates of cHL, All Ages, Both Sexes, Cases per 100,000 Population, 2009?2029
Figure 3: Sources Used for Diagnosed Incident Cases of HL, cHL, and NLPHL
Figure 4: Sources Used for Diagnosed Incident Cases of cHL by Stage
Figure 5: Sources Used for Diagnosed Incident Cases of cHL Subtypes
Figure 6: Sources Used for Five-Year Diagnosed Prevalent Cases of cHL
Figure 7: 8MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2019
Figure 8: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, N, 2019
Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of cHL, Both Sexes, N, 2019
Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of cHL, All Ages, N, 2019
Figure 11: 8MM, Diagnosed Incident Cases of cHL by Cancer Stage at Diagnosis, Both Sexes, All Ages, N, 2019
Figure 12: 8MM, Diagnosed Incident Cases of cHL by Cancer Subtypes, Both Sexes, All Ages, N, 2019
Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of cHL, Both Sexes, All Ages, N, 2019 and 2029
Figure 14: 8MM, Diagnosed Incident Cases of NLPHL, Both Sexes, All Ages, N, 2019
